Group 1 - The company, Aotai Biologics (688606.SH), announced a profit distribution plan for the mid-2025 period, proposing a cash dividend of 10 yuan (before tax) for every 10 shares [1]

Core Viewpoint - Hangzhou Aotai Biotechnology Co., Ltd. announced a profit distribution plan for the first half of 2025, proposing a cash dividend of 10 yuan per 10 shares to all shareholders, which will not include stock increases or bonus shares [1] Summary by Relevant Sections - **Dividend Distribution** - The company plans to distribute a total cash dividend of 78,307,224 yuan (including tax), based on a total share capital of 79,280,855 shares, with 78,307,224 shares eligible for distribution after deducting shares held in the repurchase account [1] - **Profit Allocation** - The proposed cash dividend represents 59.32% of the net profit for the first half of 2025 [1] - **Approval and Impact** - The distribution plan has been approved by the board of directors and the supervisory board, and it does not require submission to the shareholders' meeting for approval based on the authorization from the 2024 annual shareholders' meeting. Additionally, it is stated that this plan will not have a significant impact on the company's operating cash flow [1]

Core Viewpoint - Aotai Biologics announced the completion of the stock registration for its 2022 restricted stock incentive plan, marking a significant step in its employee incentive strategy [2] Group 1 - The company received a confirmation letter from the Shanghai branch of China Securities Depository and Clearing Corporation on September 12, 2025 [2] - The number of shares vested in this phase is 438,890 shares [2] - The shares were sourced from the company's repurchase of its A-share common stock in the secondary market [2]

证券代码：688606 证券简称：奥泰生物 公告编号：2025-040 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任公司上海分公司有关业务规则的规定，杭州奥泰生物技术股份有限公司（以下 简称"公司"）于 2025 年 9 月 12 日收到中国证券登记结算有限责任公司上海分 公司出具的《过户登记确认书》，完成了公司 2022 年限制性股票激励计划（以 下简称"本次激励计划"）首次授予第三个归属期及预留授予第二个归属期归属 的股份登记工作。现将有关情况公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 杭州奥泰生物技术股份有限公司 关于 2022 年限制性股票激励计划首次授予第三个归 属期及预留授予第二个归属期归属结果的公告 （一）2022 年 6 月 27 日，公司召开第二届董事会第十五次会议，审议通过 了《关于<杭州奥泰生物技术股份有限公司 2022 年限制性股票激励计划（草案） 及其摘要>的议案》《关于<杭州奥泰生物技术股份 ...

Group 1 - The company, Aotai Biological, has nearly 100 animal/pet testing products and has been actively selling in international markets [1] - The company recognizes the significant potential of the domestic pet market and has begun to actively develop its business in this area [1]

Group 1 - The company is committed to delivering strong performance, maintaining good corporate governance, and providing positive returns to investors [1] - The company emphasizes its responsibility and obligations as a publicly listed entity, aiming to reward the trust of its investors [1]

Group 1 - The company focuses on the POCT (Point of Care Testing) segment within the in vitro diagnostic industry [1] - The main business activities include the research, production, and sales of in vitro rapid diagnostic reagents, with the primary products being rapid diagnostic reagents [1] - The company is currently not considering investments in the raw material drug or innovative drug sectors [1]

Group 1 - The company focuses on the POCT (Point of Care Testing) segment within the in vitro diagnostic industry [1] - The main business activities include the research, production, and sales of in vitro rapid diagnostic reagents, with the primary products being rapid diagnostic reagents [1] - The company is currently not considering investments in the raw material drug or innovative drug sectors [1]

Group 1 - The company, Aotai Biological (688606.SH), currently has nearly 100 animal/pet testing products and has been actively selling in international markets [1] - The company places significant emphasis on the vast potential of the domestic pet market and has begun to actively develop its domestic pet market business [1]

Core Insights - The company held a performance briefing for the first half of 2025, focusing on advancements in cutting-edge technology platforms such as fluorescence, biochemistry, and chemiluminescence to enhance competitiveness in the high-end IVD market [1] - The chemiluminescence platform, a core technology for immunodiagnostics, is being prioritized by the company, which is enhancing its existing chemiluminescence reagent menu and upgrading its POCT chemiluminescence platform [1] - A new generation of chemiluminescence immunoassay analyzers was successfully developed in the first half of 2025, achieving international leading levels in detection speed, sensitivity, and the number of detectable items, catering to diverse clinical testing needs [1] - A series of chemiluminescent diagnostic reagents developed alongside the new analyzer have reached significant milestones, with some products currently in the registration process and set to enter the market soon [1] - These technological breakthroughs and upgrades are expected to lay a solid foundation for the company's future development in the high-end IVD market, potentially creating new profit growth points in the second half of the year and beyond [1]